Current pharmacotherapy for cholestatic liver disease

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 17, 2012, Pages 2473-2484

  Carey, Elizabeth J ^a   Lindor, Keith D ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cholestasis; Liver disease; Therapy

Indexed keywords

AZATHIOPRINE; BEZAFIBRATE; BUDESONIDE; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; ETANERCEPT; FENOFIBRATE; FISH OIL; LAMIVUDINE; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; MODAFINIL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OBETICHOLIC ACID; PENICILLAMINE; PENTOXIFYLLINE; PIRFENIDONE; PLACEBO; PREDNISONE; RITUXIMAB; S ADENOSYLMETHIONINE; SILYMARIN; STEROID; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; ZIDOVUDINE;

ABDOMINAL PAIN; ADD ON THERAPY; ALPHA TOCOPHEROL DEFICIENCY; ANTIBODY BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE HEPATITIS; CHOLANGITIS; CHOLESTASIS; CHOLESTATIC LIVER DISEASE; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CORTICOSTEROID THERAPY; DIARRHEA; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HUMAN; IATROGENIC DISEASE; IMMUNOGLOBUIN G4 ASSOCIATED CHOLANGITIS; IMMUNOGLOBULIN G4 ASSOCIATED CHOLANGITIS; IMMUNOGLOBULIN G4 ASSOCIATED LIVER DISEASE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTESTINAL FAILURE ASSOCIATED LIVER DISEASE; INTRAHEPATIC CHOLESTASIS; INTRAHEPATIC CHOLESTASIS OF PREGNANCY; LIVER DISEASE; LIVER DYSFUNCTION; LOW DRUG DOSE; MONOTHERAPY; NARCOLEPSY; NAUSEA; NONHUMAN; OSTEOPENIA; OSTEOPOROSIS; PATHOPHYSIOLOGY; PREGNANCY DISORDER; PRIMARY BILIARY CIRRHOSIS; PRIMARY BILIARY CIRRHOSIS AUTOIMMUNE HEPATITIS OVERLAP SYNDROME; PRIMARY SCLEROSING CHOLANGITIS; PRURITUS; QUALITY OF LIFE; RELAPSE; RETINOL DEFICIENCY; REVIEW; SLEEP DISORDERED BREATHING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VITAMIN D DEFICIENCY; VITAMIN K DEFICIENCY; VOMITING;

CHOLANGITIS, SCLEROSING; CHOLESTASIS; FIBRIC ACIDS; HEPATITIS, AUTOIMMUNE; HUMANS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; URSODEOXYCHOLIC ACID;

EID: 84869852834     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.736491     Document Type: Review

References (102)

1. Prince MI, James OF. The epidemiology of primary biliary cirrhosis. Clin Liver Dis 2003;7(4):795-819
2. Prince M, Chetwynd A, Newman W, et al. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 2002;123(4):1044-51
3. Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 2006;3(6):318-28
4. Hempfling W, Dilger K, Beuers U. Systematic review: ursodeoxycholic acid-dverse effects and drug interactions. Aliment Pharmacol Ther 2003;18(10):963-72
5. Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009;50(3):808-14
6. Eaton JE, Silveira MG, Pardi DS, et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 2011;106(9):1638-45
7. Poupon R, Chretien Y, Poupon RE, et al. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987;1(8537):834-6
8. Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991;324(22):1548-54
9. Heathcote EJ, Cauch-Dudek K, Walker V, et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994;19(5):1149-56
10. Angulo P, Dickson ER, Therneau TM, et al. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol 1999;30(5):830-5
11. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005;353(12):1261-73
12. Lindor KD, Therneau TM, Jorgensen RA, et al. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 1996;110(5):1515-18
13. Poupon RE, Lindor KD, Cauch-Dudek K, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113(3):884-90
14. Corpechot C, Carrat F, Bahr A, et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005;128(2):297-303
15. ter Borg PC, Schalm SW, Hansen BE, van Buuren HR. Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol 2006;101(9):2044-50
16. Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999;354(9184):1053-60
17. Gong Y, Huang Z, Christensen E, Gluud C. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol 2007;102(8):1799-807
18. Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2002(1):CD000551
19. Zein CO, Lindor KD. Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis. Curr Gastroenterol Rep 2010;12(1):13-22
20. Dohmen K, Mizuta T, Nakamuta M, et al. Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol 2004;10(6):894-8
21. Levy C, Peter JA, Nelson DR, et al. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther 2011;33(2):235-42
22. Rudic JS, Poropat G, Krstic MN, et al. Bezafibrate for primary biliary cirrhosis. Cochrane Database Syst Rev 2012;1:CD009145
23. Song KH, Li T, Owsley E, et al. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology 2009;49(1):297-305
24. Lindor KD. Farnesoid X receptor agonists for primary biliary cirrhosis. Curr Opin Gastroenterol 2011;27(3):285-8
25. Mason A LV, Lindor K, Hirschfield G, et al. Farnesoid-X receptor agonists: A new class of drugs for the treatment of PBC? An international study evaluating the addition of INT-747 to ursodeoxycholic acid. J Hepatol 2010;52(Suppl 1):S1-2
26. Kowdley KV, Luketic VA, Jones DE, et al. The first new monotherapy therapeutic PBC study in a decade: An international study evaluating the farnesoid X receptor agonist obeticholic acid in PBC. Hepatology 2011;54(4 Suppl):416A
27. Mason AL, Lindor KD, Bacon BR, et al. Clinical trial: randomized controlled trial of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol. Aliment Pharmacol Ther 2008; Epub ahead of print 28. Spadaro A, Scrivo R, Riccieri V, Valesini G. Effect of tumor necrosis factor alpha antagonists in a patient with rheumatoid arthritis and primary biliary cirrhosis. Joint Bone Spine 2008;75(1):87-9
28. Angulo P, Patel T, Jorgensen RA, et al. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000;32(5):897-900
29. Myers R, Shaheen AA, Swain MG, et al. Rituximab for primary biliary cirrhosis (PBC) refractory to ursodeoxycholic acid (UDCA). Hepatology 2007;46:550A 31. Tsuda M, Moritoki Y, Lian ZX, et al. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology 2012;55(2):512-21
30. Kaplan MM, Schmid C, Provenzale D, et al. A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis. Gastroenterology 1999;117(5):1173-80
31. Kaplan MM, Cheng S, Price LL, Bonis PA. A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results. Hepatology 2004;39(4):915-23
32. Leung J, Bonis PA, Kaplan MM. Colchicine or methotrexate, with ursodiol, are effective after 20 years in a subset of patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol 2011;9(9):776-80
33. Combes B, Emerson SS, Flye NL, et al. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology 2005;42(5):1184-93
34. Talwalkar JA, Angulo P, Keach JC, et al. Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. J Clin Gastroenterol 2005;39(2):168-71
35. Rautiainen H, Karkkainen P, Karvonen AL, et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology 2005;41(4):747-52
36. Rabahi N, Chretien Y, Gaouar F, et al. Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone. Gastroenterol Clin Biol 2010;34(4-5):283-7
37. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010;51(6):2193-213
38. Neuhauser M, Bjornsson E, Treeprasertsuk S, et al. Autoimmune hepatitis-PBC overlap syndrome: A simplified scoring system may assist in the diagnosis. Am J Gastroenterol 2010;105(2):345-53
39. Talwalkar JA, Keach JC, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol 2002;97(5):1191-7
40. Boberg KM, Chapman RW, Hirschfield GM, et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011;54(2):374-85
41. LaRusso NF, Shneider BL, Black D, et al. Primary sclerosing cholangitis: summary of a workshop. Hepatology 2006;44(3):746-64
42. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997;336(10):691-5
43. Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51(2):660-78
44. Lindstrom L, Boberg KM, Wikman O, et al. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia. Aliment Pharmacol Ther 2012;35(4):451-7
45. Lindor KD. New treatment strategies for primary sclerosing cholangitis. Dig Dis 2011;29(1):113-16
46. Van Thiel DH, Carroll P, Abu-Elmagd K, et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: Results of an open-label preliminary trial. Am J Gastroenterol 1995;90(3):455-9
47. Talwalkar JA, Gossard AA, Keach JC, et al. Tacrolimus for the treatment of primary sclerosing cholangitis. Liver Int 2007;27(4):451-3
48. Farkkila M, Karvonen AL, Nurmi H, et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: A randomized placebo-controlled trial. Hepatology 2004;40(6):1379-86
49. Silveira MG, Torok NJ, Gossard AA, et al. Minocycline in the treatment of patients with primary sclerosing cholangitis: Results of a pilot study. Am J Gastroenterol 2009;104(1):83-8
50. Angulo P, Jorgensen RA, Kowdley KV, Lindor KD. Silymarin in the treatment of patients with primary sclerosing cholangitis: An open-label pilot study. Dig Dis Sci 2008;53(6):1716-20
51. Martin CR, Blanco PG, Keach JC, et al. The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther 2012;35(2):255-65
52. Pusl T, Beuers U. Intrahepatic cholestasis of pregnancy. Orphanet J Rare Dis 2007;2:26
53. Alsulyman OM, Ouzounian JG, Ames-Castro M, Goodwin TM. Intrahepatic cholestasis of pregnancy: Perinatal outcome associated with expectant management. Am J Obstet Gynecol 1996;175(4 Pt 1):957-60
54. Palma J, Reyes H, Ribalta J, et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J Hepatol 1997;27(6):1022-8
55. Williamson C, Hems LM, Goulis DG, et al. Clinical outcome in a series of cases of obstetric cholestasis identified via a patient support group. BJOG 2004;111(7):676-81
56. Glantz A, Marschall HU, Lammert F, Mattsson LA. Intrahepatic cholestasis of pregnancy: A randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology 2005;42(6):1399-40
57. Kondrackiene J, Beuers U, Kupcinskas L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 2005;129(3):894-901
58. Binder T, Salaj P, Zima T, Vitek L. Randomized prospective comparative study of ursodeoxycholic acid and Sadenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. J Perinat Med 2006;34(5):383-91
59. Roncaglia N, Locatelli A, Arreghini A, et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-lmethionine in the treatment of gestational cholestasis. BJOG 2004;111(1):17-21
60. Carter BA, Karpen SJ. Intestinal failure-associated liver disease: Management and treatment strategies past, present, and future. Semin Liver Dis 2007;27(3):251-8
61. Cavicchi M, Beau P, Crenn P, et al. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med 2000;132(7):525-32
62. Lloyd DA, Vega R, Bassett P, et al. Survival and dependence on home parenteral nutrition: Experience over a 25-year period in a UK referral centre. Aliment Pharmacol Ther 2006;24(8):1231-40
63. Kelly DA. Intestinal failure-associated liver disease: what do we know today? Gastroenterology 2006;130(2 Suppl 1):S70-7
64. Wiles A, Woodward JM. Recent advances in the management of intestinal failure-associated liver disease. Curr Opin Clin Nutr Metab Care 2009;12(3):265-72
65. de Meijer VE, Gura KM, Le HD, et al. Fish oil-based lipid emulsions prevent and reverse parenteral nutrition-associated liver disease: The Boston experience. JPEN J Parenter Enteral Nutr 2009;33(5):541-7
66. San Luis VA, Btaiche IF. Ursodiol in patients with parenteral nutrition-associated cholestasis. Ann Pharmacother 2007;41(11):1867-72
67. Bjornsson E. Immunoglobulin G4-associated cholangitis. Curr Opin Gastroenterol 2008;24(3):389-94
68. Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: Clinical profile and response to therapy. Gastroenterology 2008;134(3):706-15
69. Bjornsson E, Chari S, Silveira M, et al. Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy. Am J Ther 2011;18(3):198-205
70. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009;51(2):237-67
71. Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology 2009;50(1):291-308
72. Charatcharoenwitthaya P, Talwalkar JA, Angulo P, et al. Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. Dig Dis Sci 2010;55(2):476-83
73. Jones DE, Newton JL. An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. Aliment Pharmacol Ther 2007;25(4):471-6
74. Ian Gan S, de Jongh M, Kaplan MM. Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience. Dig Dis Sci 2009;54(10):2242-6
75. Silveira MG, Gossard AA, DeCook AC, et al. Modafinil in the treatment of fatigue in patients with primary biliary cirrhosis. Hepatology 2011;54(4 Suppl):1211A
76. Bergasa NV. Update on the treatment of the pruritus of cholestasis. Clin Liver Dis 2008;12(1):219-34;
77. Kuiper EM, van Erpecum KJ, Beuers U, et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology 2010;52(4):1334-40
78. Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int 2006;26(8):943-8
79. Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 2002;50(3):436-9
80. Tandon P, Rowe BH, Vandermeer B, Bain VG. The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol 2007;102(7):1528-36
81. Mayo MJ, Handem I, Saldana S, et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 2007;45(3):666-74
82. Leckie P, Tritto G, Mookerjee R, et al. 'Out-patient' albumin dialysis for cholestatic patients with intractable pruritus. Aliment Pharmacol Ther 2012;35(6):696-704
83. Pares A, Herrera M, Aviles J, et al. Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. J Hepatol 2010;53(2):307-12
84. Pusl T, Denk GU, Parhofer KG, Beuers U. Plasma separation and anion adsorption transiently relieve intractable pruritus in primary biliary cirrhosis. J Hepatol 2006;45(6):887-91
85. Hay J. Bone disease in cholestatic liver disease. Gastroenterology 1995;108:276-83
86. Carey EJ, Balan V, Kremers WK, Hay JE. Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: not just a cholestatic problem. Liver Transpl 2003;9(11):1166-73
87. Shiomi S, Masaki K, Habu D, et al. Calcitriol for bone disease in patients with cirrhosis of the liver. J Gastroenterol Hepatol 1999;14(6):547-52
88. Crippin JS, Jorgensen RA, Dickson ER, Lindor KD. Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. Am J Gastroenterol 1994;89(1):47-50
89. Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 2002;50(Suppl 1):i1-9
90. Guanabens N, Pares A, Ros I, et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol 2003;98(10):2268-74
91. Zein CO, Jorgensen RA, Clarke B, et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 2005;42(4):762-71
92. Pares A, Cerda D, Monegal A, et al. Monthly ibandronate vs. weekly alendronate in the treatment of osteoporosis associated with primary biliary cirrhosis: similar efficacy but different adherence. J Hepatol 2010;52:S79
93. Treeprasertsuk S, Silveira MG, Petz JL, Lindor KD. Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis. Am J Ther 2011;18(5):375-81
94. Menon KV, Angulo P, Boe GM, Lindor KD. Safety and efficacy of estrogen therapy in preventing bone loss in primary biliary cirrhosis. Am J Gastroenterol 2003;98(4):889-92
95. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and Estrogen/progestin Replacement Study follow-up (HERS II). Jama 2002;288(1):49-57
96. Tanaka K, Sakai H, Hashizume M, Hirohata T. Serum testosterone:estradiol ratio and the development of hepatocellular carcinoma among male cirrhotic patients. Cancer Res 2000;60(18):5106-10
97. Floreani A, Zappala F, Fries W, et al. A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis. J Clin Gastroenterol 1997;24(4):239-44
98. Camisasca M, Crosignani A, Battezzati P. Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis. Hepatology 1994;20:633-7
99. Levy C, Harnois DM, Angulo P, et al. Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study. Liver Int 2005;25(1):117-21
100. Guanabens N, Pares A, del Rio L, et al. Sodium fluoride prevents bone loss in primary biliary cirrhosis. J Hepatol 1992;15:345-9
101. Abbott-Johnson WJ, Kerlin P, Abiad G, et al. Dark adaptation in vitamin A-deficient adults awaiting liver transplantation: improvement with intramuscular vitamin A treatment. Br J Ophthalmol 2011;95(4):544-8
102. Sokol RJ, Balistreri WF, Hoofnagle JH, Jones EA. Vitamin E deficiency in adults with chronic liver disease. Am J Clin Nutr 1985;41(1):66-72